After a nay from NICE, Scotland says aye to J&J’s SpravatoNHS patients with treatment-resistant depression in Scotland will be able to access Johnson & Johnson’s Spravato, a drug Share XAfter a nay from NICE, Scotland says aye to J&J’s Spravatohttps://pharmaphorum.com/news/after-a-nay-from-nice-scotland-says-aye-to-jjs-spravato/
NICE recommends regular NHS funding for Roche’s lymphoma drug PolivyNICE has recommended regular NHS funding for Roche’s Polivy in certain lymphoma patients in final draft guidance, overturning Share XNICE recommends regular NHS funding for Roche’s lymphoma drug Polivyhttps://pharmaphorum.com/news/nice-recommends-regular-nhs-funding-for-roches-lymphoma-drug-polivy/
Novartis’ Mayzent, Roche’s Polivy head latest crop of CHMP approvalsThe EMA’s human medicines advisory committee recommended approval of five novel medicines at its November meeting, including Novartis’ Share XNovartis’ Mayzent, Roche’s Polivy head latest crop of CHMP approvalshttps://pharmaphorum.com/news/novartis-mayzent-roches-polivy-head-latest-crop-of-chmp-approvals/
